We use cookies to ensure the best user experience. By using the page, you accept the usage of cookies. Read more about cookies

Skip to Content

Sivua ei löydy kielellä Suomi. Siirry fimea.fin suomenkieliselle etusivulle. Peruuta

Sidan finns inte på svenska. Tillbaka till den svenskspråkiga förstasidan av fimea.fi. Ångra

EN

Front page
For public
Databases and registers
Development and HTA
Marketing Authorisations
Medical devices
Pharmaceutical safety and information
Pharmacies
Supervision
Veterinary
About us

SearchBar

page search
medicine search

Choose search type page search medicine search

Search from site...

Search

Search field

Move to advanced medicine search

Medicine search

Contact Information

Sivua ei löydy kielellä Suomi. Siirry fimea.fin suomenkieliselle etusivulle. Peruuta

Sidan finns inte på svenska. Tillbaka till den svenskspråkiga förstasidan av fimea.fi. Ångra

EN

About us

fimea.fi

fimea.fi
About us
Frequently asked questions
Answers

Asset Publisher

null How soon after submitting the application will I receive the invoice?

How soon after submitting the application will I receive the invoice?

We will send the invoice after the pre-inspection has been completed.

10 Nov 2015

Back to previous page

Frequently asked questions

fimea.fi
About us
Frequently asked questions
Answers

Front page
For public
Databases and registers
Development and HTA
Marketing Authorisations
Medical devices
Pharmaceutical safety and information
Pharmacies
Supervision
Veterinary
About us

Contact us
Frequently asked questions
Forms

Contact information

P.O. Box 55, FI-00034 FIMEA, FINLAND

Switchboard: +358 29 522 3341

firstname.lastname@fimea.fi

© Fimea 2020

Administrative sector of the Ministry of Social Affairs and Health

The Finnish Medicines Agency Fimea is the national competent authority for regulating pharmaceuticals. As a central administrative agency operating under the Ministry of Social Affairs and Health it promotes the health and safety of the population by regulating medicinal, blood and tissue products, and by developing the pharmaceuticals sector.